全部所有文章
UBP Receives Nomination from Biologics Manufacturing Asia (BMA)
BMA is a crucial discussion forum for international biopharmaceutical companies. At the forum, more than 150 enterprises including Amgen, Genentechm, Lonza Pharma/Biotech, Novartis, WuXi Biologic, Samsung Bioepis, LG Life Science, Celltrion, Eli Lilly and Shire will participate in BMA and hundreds of executives will be in attendance.
In his presentation, Dr. Wang will focus on UBP’s latest results of cell line development/cell engineer technology and cell culture process development. UBP illustrates that it only takes 9 months to confirm cell culture development from cell line development to 50L bioreactor. The average 4-month cell line production exceeds 1g/L and following the 4-month process could elevate the productivity to 3~5 g/L. Furthermore, UBP uses a hybrid of single-use technology and perfusion cell culture technology to accelerate the development process. UBP use its own data as an example to demonstrate that UBP and other international biopharmaceutical factories are highly competitive.and that UBP possesses an international competitiveness in antibody drug development.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind. For more information, please visit https://www.ubpglobal.com/
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.
Contact
Victor Run-Ben Sun
Spokesperson and Vice President of Public Affairs
+886-978-067-006
PR@unitedbiopharma.com
victor.sun@unitedbiopharma.com